Rare, protein-truncating variants in <i>ATM</i>, <i>CHEK2</i> and <i>PALB2</i>, but not <i>XRCC2</i>, are associated with increased breast cancer risks

Abstract

Truncating variants in <i>PALB2</i> are associated with a higher risk of BC than those in <i>ATM</i> or <i>CHEK2</i>. A substantial risk of BC due to truncating <i>XRCC2</i> variants can be excluded.